TY - JOUR
T1 - Pneumocystis jiroveci pneumonia in an atypical host
AU - Reinbolt, Raquel E.
AU - Alam, Shadia
AU - Layman, Rachel
AU - Shapiro, Charles
AU - Lustberg, Maryam
N1 - Funding Information:
This study was approved and funded by the National Comprehensive Cancer Network (NCCN) from general research support provided by Cephalon, Inc.
Funding Information:
R. Layman received research funding from the National Comprehensive Cancer Network to conduct the clinical trial. All other authors state that they have no conflicts of interest.
PY - 2012/4
Y1 - 2012/4
N2 - • Pneumocystis jiroveci pneumonia (PCP) commonly manifests in the immunocompromised host with human immunodeficiency virus or hematologic malignancies. PCP infection in the solid tumor population is a rare phenomenon, particularly in patients with breast cancer. We describe a case of PCP in a patient with metastatic breast cancer after treatment with bendamustine, a chemotherapeutic agent associated with profound lymphopenia. • In the solid tumor population, risk factors for PCP include lymphopenia, steroid use, dose intensity of chemotherapy, and certain chemotherapeutic agents (eg, bendamustine), which can cause lymphopenia. • As demonstrated by our patient, those patients with solid tumor malignancy and concurrent PCP present atypically, decompensate rapidly, and have high mortality rates, which underscores the importance of making a timely diagnosis. • We will discuss the need to better characterize those non-human immunodeficiency virus immunocompromised patients who have profound and persistent lymphopenia and who may benefit from prophylaxis.
AB - • Pneumocystis jiroveci pneumonia (PCP) commonly manifests in the immunocompromised host with human immunodeficiency virus or hematologic malignancies. PCP infection in the solid tumor population is a rare phenomenon, particularly in patients with breast cancer. We describe a case of PCP in a patient with metastatic breast cancer after treatment with bendamustine, a chemotherapeutic agent associated with profound lymphopenia. • In the solid tumor population, risk factors for PCP include lymphopenia, steroid use, dose intensity of chemotherapy, and certain chemotherapeutic agents (eg, bendamustine), which can cause lymphopenia. • As demonstrated by our patient, those patients with solid tumor malignancy and concurrent PCP present atypically, decompensate rapidly, and have high mortality rates, which underscores the importance of making a timely diagnosis. • We will discuss the need to better characterize those non-human immunodeficiency virus immunocompromised patients who have profound and persistent lymphopenia and who may benefit from prophylaxis.
KW - Bendamustine
KW - Breast Cancer
KW - PCP
KW - Solid Tumor
UR - http://www.scopus.com/inward/record.url?scp=84858952290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858952290&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2011.10.003
DO - 10.1016/j.clbc.2011.10.003
M3 - Article
C2 - 22133356
AN - SCOPUS:84858952290
SN - 1526-8209
VL - 12
SP - 138
EP - 141
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 2
ER -